InvestorsHub Logo
Followers 77
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Monday, 12/04/2017 7:45:25 AM

Monday, December 04, 2017 7:45:25 AM

Post# of 2850
The results look good

“BL-8040 in combination with HiDAC was found to be safe and well tolerated, and the response rate was 38% (6/16). Median overall survival was 11.1 (1-28) months, the estimated one-year survival rate was 37.5% and the estimated two-year survival rate was 28.5%, compared to historical data for patients treated only with HiDAC showing overall survival of approximately 6.1 months.

Furthermore, the subset of patients exhibiting a response showed prolonged overall survival, with estimated one-year and two-year survival rates of 60%
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLRX News